Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

347
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
347
Sustainable Development01:43

Sustainable Development

15.1K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.1K
Development of the Lymphatic System01:15

Development of the Lymphatic System

2.1K
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
2.1K
Language Development01:22

Language Development

916
Children master language quickly and with relative ease, supported by both biological predisposition and reinforcement. B. F. Skinner (1957) proposed that language is learned through reinforcement, while Noam Chomsky (1965) argued that language acquisition mechanisms are biologically determined.
The critical period for language acquisition suggests that the ability to acquire language is at its peak early in life. As people age, this proficiency decreases. Language development begins very...
916
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

447
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
447
Development of Immunocompetence01:22

Development of Immunocompetence

903
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
903

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-type specific methylation patterns of MTAP in human samples and cell lines.

Clinical epigenetics·2026
Same author

Potent anti-tumor activity of CD98hc-targeted antibody-drug conjugates in ovarian cancer.

Signal transduction and targeted therapy·2026
Same author

From trial-and-error to inverse design: how AI is redefining drug delivery systems.

Drug discovery today·2026
Same author

Cooperative molecular interaction networks govern PARP1 inhibitor selectivity and binding affinity.

PLoS computational biology·2026
Same author

Correction to: Rational design of lipid-based nanoparticles for targeted anticancer therapies.

Drug delivery and translational research·2026
Same author

Guanidine-Based Ligands in Bioinorganic Chemistry: Coordination Modes and Applications in Anticancer Metallodrugs.

Bioinorganic chemistry and applications·2026

Related Experiment Video

Updated: Feb 4, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.4K

Refining Early Antitumoral Drug Development.

Alberto Ocaña1, Sara García-Alonso2, Eitan Amir3

  • 1Translational Research Unit, Albacete University Hospital, Albacete, Spain; CIBERONC, Madrid, Spain.

Trends in Pharmacological Sciences
|October 4, 2018
PubMed
Summary

Developing new oncology drugs faces a high failure rate, with 95% of Phase I candidates not reaching market. This analysis explores reasons for failure and proposes solutions to improve antitumor drug development success.

Keywords:
drug developmentoncology

More Related Videos

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.9K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Related Experiment Videos

Last Updated: Feb 4, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.4K
Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.9K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Area of Science:

  • Oncology
  • Drug Development
  • Pharmaceutical Research

Background:

  • The development of novel antitumor drugs is critical for advancing cancer treatment.
  • However, the oncology drug development pipeline is characterized by exceptionally high attrition rates.
  • A significant majority of drugs entering clinical trials fail to gain regulatory approval.

Purpose of the Study:

  • To investigate the primary causes contributing to the high failure rate in oncology drug development.
  • To identify and suggest actionable strategies for enhancing the success probability of new antitumor agents.
  • To provide insights for optimizing the preclinical and clinical stages of cancer drug discovery.

Main Methods:

  • Review of existing literature on oncology drug development failures.
  • Analysis of common reasons for attrition across different phases of clinical trials.
  • Synthesis of proposed solutions and best practices from scientific and industry experts.

Main Results:

  • Key failure factors include lack of efficacy, unacceptable toxicity, poor pharmacokinetic properties, and inadequate trial design.
  • Challenges in patient selection and biomarker identification contribute significantly to late-stage failures.
  • The high cost and lengthy timelines exacerbate the impact of failures.

Conclusions:

  • Addressing the root causes of failure requires a multi-faceted approach, including improved preclinical models and biomarker strategies.
  • Enhanced collaboration between academia, industry, and regulatory bodies can streamline the development process.
  • Implementing innovative trial designs and adaptive methodologies may increase the efficiency of antitumor drug development.